Camurus Annual Report for 2023
Lund, Sweden — 28 March 2024 — Camurus (CAMX) today announces that the Annual Report for 2023 now is available at the company’s website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).
The Annual Report also includes Camurus’ sustainability report.
Fredrik Tiberg, President and CEO:
“Camurus performed strongly during the year towards our vision of becoming a global, long-term sustainable, specialty pharmaceutical company focused on the development of life-changing medicines for people with severe and chronic diseases. Buvidal® weekly and monthly buprenorphine depots are now available in over 20 countries on four continents, helping to improve the lives of people with opioid dependence. Brixadi® was launched in the US in September, following market approval from the US Food and Drug Administration (FDA). We received positive results from two Phase 3 studies of CAM2029 for the treatment of acromegaly in the ACROINNOVA program, submitted a marketing authorization application (NDA) for Oclaiz™ to the FDA, and completed enrollment in the SORENTO study of CAM2029 in people with neuroendocrine tumors. During the year, we also initiated new development programs and strengthened our sustainability work.”
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information is information that Camurus AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10.00 am CET on 28 March, 2024.
